Shares in biopharmaceutical ASX-star stock CSL Limited (ASX: CSL) can't be called cheap, but UBS still has a buy rating on the stock, which was sitting at $169.71 at the time of writing.
UBS labels the stock a buy with a price target of $175 with US industry data convincing the broker there's still plenty of growth potential in the pipeline for the company.
CSL is currently trading about 20% above its 200-day moving average in an upward trend, with peer Cochlear Limited (ASX: COH) also trending upwards in a similar fashion with Cochlear's price up 1% to $197.01 today and no signs of a slowdown.
Both companies have likely fared well from a plunging Australian dollar thanks to their US earnings, while globally-focused healthcare players like Sonic Healthcare Limited (ASX: SHL) have also begun to correct from a recent downturn with prices heading up 0.6% to $23.90 at the time of writing. This as the company works to strengthen its presence overseas.
